Results 41 to 50 of about 53,318 (258)

Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]

, 2020
OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD, Akgün, T, Camm, AJ, Emren, V, Kanat, S, Karacağlar, E, Kepez, A, Kul, Ş, Tülüce, K, Türk, UÖ, Yakar Tülüce, S, Özel, E, Şimşek, E   +12 more
core   +1 more source

Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life‐threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK‐wide survey of local hospital protocols for the use of andexanet alfa suggested that practice ...
Louis Fisher, Richard Buka, Rosalind Byrne, Stephen Black, Helen J. Curtis, Christopher Wood, Andrew Brown, Sebastian Bacon, Richard Croker, Ben Goldacre, Brian MacKenna, Victoria Speed   +11 more
wiley   +1 more source

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation

Pharmaceutics
This study aimed to investigate the impact of the drug–drug interaction between rivaroxaban and amiodarone on the clinical outcomes in patients with non-valvular atrial fibrillation (NVAF), focusing on pharmacokinetic and pharmacodynamic (PK/PD) aspects.
Huamin Ding, Zi Wang, Jia Wang, Yao Yao, Chi Zhang, Houwen Lin, Yong Zhou, Zhichun Gu, Qianzhou Lv, Xiaoye Li   +9 more
doaj   +1 more source

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

BMC Cardiovascular Disorders, 2017
Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
Faye L. Norby, Lindsay G.S. Bengtson, Pamela L. Lutsey, Lin Y. Chen, Richard F. MacLehose, Alanna M. Chamberlain, Ian Rapson, Alvaro Alonso   +7 more
doaj   +1 more source

Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation

CJC Open, 2021
Rivaroxaban is commonly used for prevention of thromboembolic diseases in patients with atrial fibrillation. We report a case of an 86-year-old man with hypertension, chronic kidney disease, type 2 diabetes mellitus, dyslipidemia, and atrial fibrillation
Jiaming (Calvin) Liang, MD, MSc, Karanvir Raman, BBA, Siu Him Chan, MD, A. Yashar Tashakkor, MD   +3 more
doaj   +1 more source

Simultaneous Repair of Iatrogenic Left Atrial and Aortic Perforations Using Ductus Arteriosus Occluders: A Case Report

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Iatrogenic perforation of the left atrium and aorta during transseptal puncture (TSP) is a rare but potentially life‐threatening complication. This report presents the case of an elderly male patient with a 20‐year history of atrial fibrillation who experienced this complication during a scheduled left atrial appendage closure procedure ...
Zhihao Wu, Shumin Ouyang, Minqi Liao, Lihua Chen, Haixian Yin, Jianping Zhou, Suxia Guo   +6 more
wiley   +1 more source

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. [PDF]

, 2019
IntroductionPatient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence.
Becker, Richard C, Berkowitz, Scott D, Breithardt, Guenter, Fox, Keith AA, Hacke, Werner, Halperin, Jonathan L, Hankey, Graeme J, Hellkamp, Anne S, Mahaffey, Kenneth W, Nessel, Christopher C, Patel, Manesh R, Piccini, Jonathan P, Rodriguez, Fatima, Singer, Daniel E, Ungar, Leo   +14 more
core   +1 more source

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]

, 2018
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo, Chiarotti, Flavia, Dragoni, Francesco, Iori, Anna Paola, La Rocca, Ursula   +4 more
core   +1 more source

Endovascular Stenting for Pulmonary Vein Stenosis Following Atrial Fibrillation Ablation: From Diagnosis to Intervention

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Pulmonary vein stenosis (PVS) is an uncommon but serious complication of atrial fibrillation (AF) ablation, often misinterpreted as primary pulmonary disease. Timely identification is essential to prevent irreversible injury and to guide appropriate referral for interventional management. Case Presentations Through the discussion of
Cristina Aurigemma, Marco Busco, Francesco Bianchini, Gabriella Locorotondo, Francesca Graziani, Annalisa Pasquini, Enrico Romagnoli, Mattia Lunardi, Lazzaro Paraggio, Francesco Varone, Andrea Smargiassi, Bruno Iovene, Riccardo Marano, Carlo Trani, Francesco Burzotta   +14 more
wiley   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources